Table 1.
Patients’ characteristics at enrollment.
| Sex (M/F) | 152/57 (72.7%/27.3%) |
| Nationality (Greek/Other) | 187/22 (89.5%/10.5%) |
| Age (years) | 67 (15) |
| Weight (kg) | 85 (110) |
| BMI (kg/m2) | 29.2 98.4) |
| HbA1c (%) | 7.2 (2.6) |
| LDL (mg/dL) | 89 (61) |
| HDL (mg/dL) | 43.5 (16) |
| Tg (mg/dL) | 147 (100) |
| FIB-4 | 1.02 (0.5) |
| Metformin (Yes/No) | 153/56 (73.2%/26.8%) |
| DPP-4 inhibitors (Yes/No) | 47/162 (22.5%/77.5%) |
| SGLT-2 inhibitors (Yes/No) | 64/145 (30.6%/69.4%) |
| GLP-1 analogs (Yes/No) | 69/140 (33%/67%) |
| Sulfonylureas (Yes/No) | 22/187 (10.5%/89.5%) |
| Pioglitazone (Yes/No) | 7/202 (3.3%/96.7%) |
| Insulin (Yes/No) | 79/130 (37.8%/62.2%) |
| Hypertension (Yes/No) | 96/113 (45.9%/54.1%) |
| CKD (Yes/No) | 14/195 (6.7%/93.3%) |
| CVD (Yes/No) | 76/133 (36.4%/63.6%) |
| Extrahepatic cancer (Yes/No) | 39/160 (18.7%/81.3%) |
| FIB-4 > 1.3 (Yes/No) | 59/150 (28.2%/71.8%) |
Variables are expressed as median value and interquartile range (IQR) or number of cases (percentages). BMI: body mass index; HbA1c: glycated hemoglobulin A1; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglycerides; DPP-4: dipeptidyl peptidase-4; SGLT-2: Sodium-Glucose Transport Protein-2; GLP-1: glucagon-like peptide-1; CKD: chronic kidney disease; CVD: cardiovascular disease. The table displays patients’ lipid values and antidiabetic treatment at the study's enrollment time.